Supplementary Online Content


**eTable.** Clinical and Radiological Presentation and Treatment of ONI of PCNSL (n = 7)

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable. Clinical / radiological presentation and treatment of optic nerve infiltration of primary CNS lymphoma (N = 7)**

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Onset Clinical presentation</th>
<th>Radiological presentation</th>
<th>Treatment</th>
<th>Outcome Clinical presentation</th>
<th>Radiological presentation</th>
<th>Treatment</th>
<th>Outcome Clinical presentation</th>
<th>Radiological presentation</th>
<th>Treatment</th>
<th>Outcome Clinical presentation</th>
<th>Radiological presentation</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ONI</td>
<td>Parenchymal enhancing lesions</td>
<td>R-MBVP- Cytarabine + HDCASCT</td>
<td>MRI: CR VA: 6/10</td>
<td>N/A (discovered on routine MRI)</td>
<td>Ventricular and parenchymal enhancement</td>
<td>MTX + TMZ &amp; intraventricular Rituxinab – MTX</td>
<td>MRI: PD; Best supportive care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>ONI</td>
<td>Parenchymal enhancing lesions</td>
<td>Steroids (prior to diagnosis of lymphomatous ONI), 2 MPV, followed by TMZ</td>
<td>MRI: PR VA: 0,5/10</td>
<td>Brainstem signs</td>
<td>Ventricular enhancement</td>
<td>Best supportive care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Vertigo, unilateral hemianopia</td>
<td>Parenchymal enhancing lesions</td>
<td>MTX, Lomustine, Procarbazine + it MTX, Cytarabine</td>
<td>MRI: CR</td>
<td>ONI</td>
<td>Parenchymal enhancing lesions</td>
<td>MT-A (+ oral methylprednisolone)</td>
<td>MRI: CR VA: 0,5/10</td>
<td>Left hemianopia, right arm paresis</td>
<td>Right occipital parenchymal enhancement and right brachial plexus infiltration</td>
<td>ASHAP</td>
<td>MRI: PD; Best supportive care</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>(No data available)</td>
<td>Ventricular and parenchymal enhancement</td>
<td>MTX, Lomustine, Procarbazine + it MTX, Cytarabine</td>
<td>MRI: CR</td>
<td>ONI</td>
<td>Parenchymal non-enhancing lesions</td>
<td>iv methylprednisolone followed by CYVE + HDCACST</td>
<td>MRI: CR VA: 3/10</td>
<td>Left leg paresis</td>
<td>Right paracentral parenchymal enhancement</td>
<td>Temozolomide</td>
<td>MRI: PD; ONI; Best supportive care</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Confusion, insomnia, incoherence;</td>
<td>Ventricular and parenchymal enhancement</td>
<td>MTX, Procarbazine, Vincristine, Cytarabine</td>
<td>MRI: PR</td>
<td>ONI</td>
<td>Parenchymal non-enhancing lesions</td>
<td>iv methylprednisolone followed by ICE</td>
<td>MRI: CR VA: 0,5/10</td>
<td>Confusion</td>
<td>Right temporoparietal and bitemporal parenchymal enhancement</td>
<td>Best supportive care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Cerebellar symptoms; Cerebellar and right temporal parenchymal enhancement</td>
<td></td>
<td>R-MBVP- Cytarabine + Radiation therapy</td>
<td>MRI: CR</td>
<td>N/A (discovered on routine MRI)</td>
<td>Cerebellar and right temporal parenchymal enhancing lesions</td>
<td>R-ICE (SD), R-DHAox (PR) followed by HDCASCT (PR)</td>
<td>MRI: PR</td>
<td>ONI</td>
<td>Parenchymal enhancing lesions</td>
<td>Vismodegib</td>
<td>MRI: SD VA:0/10</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Cognitive decline, gait disturbance; Non enhancing white matter lesions</td>
<td></td>
<td>MTX, Procarbazine, Vincristine, Cytarabine</td>
<td>MRI: PR</td>
<td>ONI</td>
<td>Parenchymal enhancing lesions</td>
<td>R-GEMOX</td>
<td>MRI: SD VA: 0,5/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American Medical Association. All rights reserved.
Legend to supplementary eTable

ASHAP: doxorubicin, methylprednisolone, cytarabine, cisplatin
CSF: cerebrospinal fluid
CYVE: high-dose cytarabine, etoposide
DHAOx: Dexamethasone, high-dose cytarabine, oxaliplatin
HDCASCT: high-dose chemotherapy (high-dose busulfan, cyclophosphamide, thiotepa) with autologous stem cell transplant
ICE: ifosfamide, carboplatin, etoposide
it: intrathecal
MT-A: methotrexate, temozolomide, cytarabine
MTX: methotrexate
MPV: methotrexate, procarbazine, vincristine
ONI: optic nerve infiltration
PCNSL: primary CNS lymphoma
R-MBVP: rituximab, methotrexate, carmustine, carboplatin, prednisolone
R-AraC: rituximab, high-dose cytarabine
R-GEMOX: rituximab, gemcitabine, oxaliplatin
RTx: Radiation therapy

CR: complete response
SD: stable disease
PR: partial response
PD: progressive disease

VA: visual acuity